Featured Research

from universities, journals, and other organizations

Novel way to treat drug-resistant brain tumor cells

Date:
June 1, 2012
Source:
University of Wisconsin-Madison
Summary:
New research explains why the incurable brain cancer, glioblastoma multiforme (GBM), is highly resistant to current chemotherapies.

New research from the University of Wisconsin-Madison explains why the incurable brain cancer, glioblastoma multiforme (GBM), is highly resistant to current chemotherapies.

Related Articles


The study, from the brain-tumor research lab of Dr. John Kuo, assistant professor of neurological surgery and human oncology at UW School of Medicine and Public Health, also reports success for a combination therapy that knocks out signaling of multiple members of the epidermal growth factor receptor (EGFR) family in brain-cancer cells.

The late U.S. Sen. Edward M. Kennedy died of GBM in 2009. People diagnosed with GBM live on average for only 15 months after diagnosis, even after undergoing aggressive surgery, radiation and chemotherapy. Earlier research from Dr. Kuo and other scientists showed that GBM cancer stem cells escape current treatments and proliferate rapidly to cause tumor recurrence.

Several years ago, research suggested that a drug engineered to target EGFR signaling might work against GBM because many brain cancers carried EGFR mutations. Excessive and abnormal EGFR signaling spurs the growth of cancer cells. Although cetuximab, a monoclonal-antibody drug, was successful in clinical trials for patients with lung, colorectal, and head and neck cancers, it failed against GBM.

Research by Dr. Paul Clark, a scientist in Kuo's lab and the study's lead author, shows why. When cetuximab treatment switches off EGFR activity and should inhibit cancer-cell growth, cancer stem cells compensate by turning on two other EGFR family receptors (ERBB2 and ERBB3) and continue to grow. One of these receptors, ERBB2, is implicated in certain types of chemotherapy-resistant breast cancer. Fortunately, another novel drug already approved by the FDA, lapatinib, inhibits ERBB2 activity and signaling by multiple EGFR members.

This study shows that cancer stem-cell growth was markedly inhibited by lapatinib treatment, which results in combined knockout of multiple EGFR family members.

"This is good news, because these drugs target an important mechanism for the (GBM) cancer cells to grow so quickly and evade current therapies, and these molecularly targeted drugs are also well-tolerated by patients and have minimal side effects," Dr. Clark said.

The paper was published in the most recent issue of Neoplasia, an international journal for oncology research.

Kuo, director of the Comprehensive Brain Tumor Program at UW Health and chair of the Carbone Cancer Center brain tumor group, said that results of several brain cancer clinical trials with these novel drugs and other new strategies are pending or underway.


Story Source:

The above story is based on materials provided by University of Wisconsin-Madison. Note: Materials may be edited for content and length.


Journal Reference:

  1. Paul A. Clark, Mari Iida, Daniel M. Treisman, Haviryaji Kalluri, Sathyapriya Ezhilan, Michael Zorniak, Deric L. Wheeler and John S. Kuo. Activation of Multiple ERBB Family Receptors Mediates Glioblastoma Cancer Stem–like Cell Resistance to EGFR- Targeted Inhibition. Neoplasia, 2012 DOI: 10.1596/neo.12432

Cite This Page:

University of Wisconsin-Madison. "Novel way to treat drug-resistant brain tumor cells." ScienceDaily. ScienceDaily, 1 June 2012. <www.sciencedaily.com/releases/2012/06/120601231758.htm>.
University of Wisconsin-Madison. (2012, June 1). Novel way to treat drug-resistant brain tumor cells. ScienceDaily. Retrieved October 31, 2014 from www.sciencedaily.com/releases/2012/06/120601231758.htm
University of Wisconsin-Madison. "Novel way to treat drug-resistant brain tumor cells." ScienceDaily. www.sciencedaily.com/releases/2012/06/120601231758.htm (accessed October 31, 2014).

Share This



More Health & Medicine News

Friday, October 31, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Melafind: Spotting Melanoma Without a Biopsy

Melafind: Spotting Melanoma Without a Biopsy

Ivanhoe (Oct. 31, 2014) The MelaFind device is a pain-free way to check suspicious moles for melanoma, without the need for a biopsy. Video provided by Ivanhoe
Powered by NewsLook.com
Battling Multiple Myeloma

Battling Multiple Myeloma

Ivanhoe (Oct. 31, 2014) The answer isn’t always found in new drugs – repurposing an ‘old’ drug that could mean better multiple myeloma treatment, and hope. Video provided by Ivanhoe
Powered by NewsLook.com
Chronic Inflammation and Prostate Cancer

Chronic Inflammation and Prostate Cancer

Ivanhoe (Oct. 31, 2014) New information that is linking chronic inflammation in the prostate and prostate cancer, which may help doctors and patients prevent cancer in the future. Video provided by Ivanhoe
Powered by NewsLook.com
Sickle Cell: Stopping Kids’ Silent Strokes

Sickle Cell: Stopping Kids’ Silent Strokes

Ivanhoe (Oct. 31, 2014) Blood transfusions are proving crucial to young sickle cell patients by helping prevent strokes, even when there is no outward sign of brain injury. Video provided by Ivanhoe
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins